AstraZeneca

We push the boundaries of science to deliver life-changing medicines.

www.astrazeneca.com

AstraZeneca Korea

CEO
Juno Kim

Location
21F ASEM Tower, 517 Yeong-dong-daero, Gangnam-gu, Seoul, Korea

Specialty
Oncology, Cardiovascular, Renal & Metabolism and Respiratory

Tel / Fax / E-mail
T. 82-2-2188-0800
F. 82-2-2188-0852
E. webmaster.korea@astrazeneca.com

AstraZeneca Korea is a science-led biopharmaceutical business delivering life changing medicines to patients through innovative science and excellence in development and commercialization. It focuses on the development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory.

Main Products

Oncology	Cardiovascular and Metabolism	Respiratory
IRESSA (Non-small cell lung cancer)		
TAGRISSO (Non-small cell lung cancer)	Forxiga (Type 2 diabetes)	
Imfinzi (Non-small cell lung cancer)	Brilinta (Acute coronary syndrome)	Symbicort (Asthma, COPD)
Lynparza (Ovarian Cancer)		
Faslodex (Breast Cancer)		

R&D Pipeline

Phase I — 18 New Molecular Entities

- AZD0466 BCL2/xL haematological and solid tumours
- AZD1390 glioblastoma
- AZD4573 CDK9 haematological malignancies
- AZD5153 BRD4 solid tumours, haematological malignancies
- AZD5991 MCL1 haematological malignancies
- AZD9496 SERD ER+ breast
- Calquence+ceralasertib (AZD6738) BTK+ATR haematological tumours
- Calquence+danvatirsen BT K+STAT3 haematological m alignancies
- Imfinzi#+adavosertib# PD-L1+Wee1 solid tumours
- Imfinzi#+RT (platform) CLOVER P D-L1+RT HNSCC NSCLC SCLC
- Imfinzi#+tremelimumab PD-L1+CTLA-4 solid tumours
- Imfinzi#+tremelimumab+chemo PD-L1+CTLA-4 1L PDAC oesophageal SCLC
- Imfinzi+selumetinib# PD-L1+MEK solid tumours
- MEDI1191 IL-12 mRNA solid tumours
- MEDI2228 BCMA ADC multiple myeloma
- MEDI5083 CD40 ligand fusion protein solid tumours
- MEDI5395 INOV GMCSF solid tumours
- oleclumab+Tagrisso CD73+EGFR EGFRm NSCLC

Phase II — 27 New Molecular Entities

- adavosertib# Wee1 ovarian cancer, solid tumours
- AZD2811 Aurora solid tumours, haematological malignancies
- AZD4635 A2aR inhibitor prostate cancer
- AZD9833 SERD ER+ breast
- capivasertib# AKT breast
- capivasertib# AKT prostate
- Enhertu# ADC colorectal cancer
- Enhertu# ADC NSCLC
- Imfinzi# (platform) COAST PD-L1+multiple novel ONC therapies NSCLC
- Imfinzi# (platform) NeoCOAST PD-L1+multiple novel ONC therapies NSCLC
- Imfinzi#+AZD4635 PD-L1+A2aR prostate cancer
- Imfinzi#+AZD5069 or Imfinzi# + danvatirs en# PD-L1+(CXCR2 or STAT3) HNSCC bladder NSCLC
- Imfinzi#+Lynparza# ORION PD-L1+PARP 1L mNSCLC
- Imfinzi#+MEDI0457# PD-L1+DNA HPV vaccine HNSCC
- Imfinzi#+monalizumab# PD-L1+NKG2a solid tumours
- Imfinzi#+oleclumab PD-L1+CD73 solid tumours
- Imfinzi#+tremelimumab PD-L1+CTLA-4 gastric cancer
- Imfinzi#+tremelimumab PD-L1+CTLA-4 biliary/ract oesophageal
- Imfinzi+Lynparza# BAYOU PD-L1+PARP bladder
- Lynparza#+adavosertib# PARP+Wee1 solid tumours
- Lynparza#+AZD6738 VIOLETTE PARP+ATR breast
- Lynparza#+Imfinzi MEDICLA PARP +PD-L1 ovarian breast gastric SCL C
- MEDI5752 PD-1/CTLA-4 solid tumours
- oleclumab+AZD4635 CD73+ A2aR prostate cancer
- oleclumab+chemo or Imfinzi#+ olecl umab+chemo CD73+chemo or PD-L1+CD73+chemo pancreatic
- Tagrisso combo# TATTON EGFR+PD-L1/MEK/MET NSCLC
- Tagrisso+savolitinib# SAVANNAH EGFR+MET advanced EGFRm N SCLC

Phase III — 12 New Molecular Entities

- capivasertib+chemotherapy CA Pitalo-290 AKT+chemotherapy mTNBC 1L
- Enhertu# DESTINY-Breast 02 ADC breast
- Enhertu# DESTINY-Breast 03 ADC breast
- Enhertu# DESTINY-Breast 04 ADC breast
- Enhertu¶# DESTINY-Gastric01 ADC gastric
- Imfinzi#+-tremelimumab+chemo POSEIDON PD-L1+-CTLA-4+SoC 1L NSCLC
- Imfinzi#+-tremelimumab+CRT ADRIATIC PD-L1+/CTLA-4+CRT LS-SCLC
- Imfinzi#+tremelimumab DANUBE PD-L1+CTLA-4 1L bladder
- Imfinzi#+tremelimumab HIMALAYA PD-L1+CTLA-4 1L HCC
- Imfinzi#+tremelimumab KESTREL PD-L1+CTLA-4 1L HNSCC
- Imfinzi#+tremelimumab+SoC NILE PD-L1+CTLA-4+SoC 1L urothelial cancer
- Lynparza#+Imfinzi#+bevacizumab DUO-O PARP+PD-L1+VEGF 1L ovarian

Under Review — 2 New Molecular Entities

- Imfinzi#+-tremelimumab+SoC CASPIAN PD-L1+/CTLA-4+SoC 1L ES-SCLC
- selumetinib#¶ SPRINT MEK paediatric neurofibromatosis type-1

[1] includes novel combinations and additional indications for assets where the lead is not yet launched
Partnered and/or in collaboration; ¶ Registrational Phase II/III study

Oncology — Precision medicine approach under investigation

Phase I — 16 New Molecular Entities

- AZD0284 RORg psoriasis / respiratory
- AZD4041# orexin 1 receptor antagonist opinoid use disorder
- AZD0449 inhaled JAK inhibitor asthma
- AZD1402# inhaled IL4Ra asthma
- AZD2693 nonalcoholic steatohepatitis
- AZD5634 inhaled ENaC cystic fibrosis
- AZD6615 hypercholesterolemia CV disease
- AZD8154 Inhaled PI3Kgd asthma
- AZD8233 hypercholesterolemia cardiovascular
- AZD9977 MCR cardiovascular
- MEDI0618 PAR2 antagonist mAbosteoarthritis pain
- MEDI1341# alpha synuclein parkinson'sdisease
- MEDI1814# amyloid)alzheimer's disease
- MEDI5117# China IL6 YTE rheumatoid arthritis
- MEDI6570 LOX-1 CV disease
- MEDI7219 anti-diabetic type-2 diabetes

Phase II — 22 New Molecular Entities

- abediterol# LABA asthma / COPD
- anifrolumab# Type I IFN receptor SLE SC
- anifrolumab# Type I IFN receptor lupus nephritis
- AZD4831 MPO HFpEF
- AZD5718 FLAP coronary artery disease
- AZD7594 Inhaled SGRM asthma / COPD
- AZD7986# DPP1 COPD
- AZD8601# VEGF-A cardiovascular
- AZD8871# MABA COPD
- AZD9567 SGRM RA / respiratory
- cotadutide GLP-1/glucagon type-2 diabetes / obesity / NASH
- MEDI3506 Diabetic kidney disease
- MEDI3506 IL33 AD / COPD
- MEDI3902 Pal/PcrV Pseudomonas pneumonia
- MEDI5884# cholesterol modulation cardiovascular
- MEDI6012 LCAT cardiovascular
- MEDI7352 NGF/TNF OA pain / painful diabetic neuropathy
- roxadustat# HIF-PH inhibitor chemo induced anaemia
- suvratoxumab α-Toxin Staphylococcus pneumonia
- tezepelumab# TSLP atopic dermatitis
- tezepelumab# TSLP COPD
- verinurad URAT-1 chronic kidney disease

Phase III — 5 New Molecular Entities

- anifrolumab# TULIP Type I IFN receptor SLE
- nirsevimab (MEDI8897)# RS V mAb-YTE passive RSV im munisation
- PT027 ICS/SABA asthma
- roxadustat# HIFPH anaemia MDS
- tezepelumab# NAVIGA TOR SOURCE TSLP severe uncontrolled asthma

[1] includes novel combinations and additional indications for assets where the lead is not yet launched
Partnered and/or in collaboration; ¶ Registrational Phase II/III study

BioPharmaceuticals — Precision medicine approach under investigation